Styrax Capital LP Acquires New Stake in Guardant Health, Inc. $GH

Styrax Capital LP acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 281,589 shares of the company’s stock, valued at approximately $28,762,000. Guardant Health comprises approximately 2.2% of Styrax Capital LP’s investment portfolio, making the stock its 15th biggest holding.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC raised its stake in Guardant Health by 13.4% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 10,187 shares of the company’s stock valued at $1,040,000 after purchasing an additional 1,207 shares during the last quarter. Mariner LLC raised its stake in Guardant Health by 43.1% in the 4th quarter. Mariner LLC now owns 5,611 shares of the company’s stock valued at $572,000 after purchasing an additional 1,690 shares during the last quarter. Maven Securities LTD acquired a new position in Guardant Health in the 4th quarter valued at $2,554,000. Next Century Growth Investors LLC acquired a new position in Guardant Health in the 4th quarter valued at $1,888,000. Finally, First Turn Management LLC acquired a new position in Guardant Health in the 4th quarter valued at $27,750,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Stock Down 1.9%

Shares of GH opened at $127.34 on Wednesday. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $135.00. The company has a market capitalization of $16.89 billion, a PE ratio of -37.56 and a beta of 1.61. The stock has a fifty day simple moving average of $104.90 and a two-hundred day simple moving average of $102.36.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Robert W. Baird assumed coverage on Guardant Health in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Leerink Partners raised their target price on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Royal Bank Of Canada initiated coverage on Guardant Health in a research note on Thursday, June 11th. They issued an “outperform” rating and a $185.00 target price for the company. Finally, Canaccord Genuity Group raised their target price on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and a consensus target price of $141.95.

Insiders Place Their Bets

In related news, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the sale, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This trade represents a 4.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,000 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $130.06, for a total value of $130,060.00. Following the sale, the director directly owned 639 shares of the company’s stock, valued at $83,108.34. The trade was a 61.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 449,006 shares of company stock worth $51,148,938. 5.60% of the stock is currently owned by company insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.